A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease

Abstract Introduction This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild‐to‐moderate Alzheimer's disease (AD) on background donepezil 10 mg/day. Methods A randomized, double‐blind, placebo‐contro...

Full description

Bibliographic Details
Main Authors: Pradeep J. Nathan, S. Babli Millais, Alex Godwood, Odile Dewit, David M. Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones, Geor Bakker, Paul T. Maruff, Gregory A. Light, Alastair J.H. Brown, Malcolm Peter Weir, Miles Congreve, Tim Tasker
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
attention
cholinergic
clinical trial
cognition
Cogstate neuropsychological test battery
Online Access:https://doi.org/10.1002/trc2.12273

Internet

https://doi.org/10.1002/trc2.12273

Similar Items